Article

Feds: Jury awards are to blame for insurance hikes

Author(s):

Bob Gatty

Washington-Congress has been told by its chief investigative agency thatincreasing medical liability awards, indeed, are contributing to skyrocketingpremium costs for many physicians, but that fact is not having a widespreadimpact on patients' access to health care.

Related Videos
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Colin Goudelocke, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Amy E. Krambeck, MD, answers a question during a Zoom video interview
1 expert in this video
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Related Content
Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome
March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke
"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke
"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke
The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
Identifying unique therapeutic targets for chromophobe kidney cancer
March 6th 2025

Identifying unique therapeutic targets for chromophobe kidney cancer

David A. Braun, MD, PhD Hannah Clarke
“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.
© 2025 MJH Life Sciences

All rights reserved.